Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124382232 | 12438223 | 2 | F | 201511 | 20160622 | 20160606 | 20160701 | EXP | US-JNJFOC-20160523755 | JANSSEN | 52.28 | YR | A | F | Y | 0.00000 | 20160701 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124382232 | 12438223 | 1 | PS | STELARA | USTEKINUMAB | 1 | Subcutaneous | N | FGS21MA | 125261 | 90 | MG | SOLUTION FOR INJECTION | ||||||
| 124382232 | 12438223 | 2 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | N | 103772 | LYOPHILIZED POWDER | |||||||||
| 124382232 | 12438223 | 3 | C | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Unknown | 0 | UNSPECIFIED | ||||||||||
| 124382232 | 12438223 | 4 | C | PROAIR HFA | ALBUTEROL SULFATE | 1 | Unknown | AS NEEDED | 0 | INHALATION | |||||||||
| 124382232 | 12438223 | 5 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 0 | 300 | MG | CAPSULE | TID | |||||||
| 124382232 | 12438223 | 6 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 5-325 MG/3-4 TIMES DAILY | 0 | TABLET | |||||||||
| 124382232 | 12438223 | 7 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 0 | 40 | MG | TABLET | BID | |||||||
| 124382232 | 12438223 | 8 | C | KLOR-CON | POTASSIUM CHLORIDE | 1 | Oral | 0 | TABLET | ||||||||||
| 124382232 | 12438223 | 9 | C | PREDNISONE. | PREDNISONE | 1 | Oral | 0 | 5 | MG | TABLET | BID | |||||||
| 124382232 | 12438223 | 10 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | FOR ^STOMACH^ | 0 | 20 | MG | CAPSULE | BID | ||||||
| 124382232 | 12438223 | 11 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | 0 | 40 | MG | TABLET | ||||||||
| 124382232 | 12438223 | 12 | C | FOLIC ACID. | FOLIC ACID | 1 | Oral | 0 | 1 | MG | TABLET | ||||||||
| 124382232 | 12438223 | 13 | C | VITAMIN D2 | ERGOCALCIFEROL | 1 | Oral | 50000 U/ WEEKLY | 0 | CAPSULE | |||||||||
| 124382232 | 12438223 | 14 | C | METHOTREXATE. | METHOTREXATE | 1 | Oral | 0 | 2.5 | MG | TABLETS | ||||||||
| 124382232 | 12438223 | 15 | C | CETIRIZINE | CETIRIZINE HYDROCHLORIDE | 1 | Oral | DAILY | 0 | 10 | MG | TABLET | |||||||
| 124382232 | 12438223 | 16 | C | MONTELUKAST | MONTELUKAST SODIUM | 1 | Oral | ORAL | 0 | 10 | MG | TABLET | |||||||
| 124382232 | 12438223 | 17 | C | ADVAIR HFA | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Unknown | 0 | UNSPECIFIED | ||||||||||
| 124382232 | 12438223 | 18 | C | ZOLPIDEM TARTRATE. | ZOLPIDEM TARTRATE | 1 | Oral | DAILY | 0 | 10 | MG | TABLET | |||||||
| 124382232 | 12438223 | 19 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | DAILY | 0 | 20 | MG | TABLET | |||||||
| 124382232 | 12438223 | 20 | C | PRAMIPEXOLE. | PRAMIPEXOLE | 1 | Oral | 1-2 TABLETS DAILY | 0 | 25 | MG | TABLET | |||||||
| 124382232 | 12438223 | 21 | C | PILOCARPINE. | PILOCARPINE | 1 | Oral | 2-3 TIMES A DAY | 0 | TABLET | |||||||||
| 124382232 | 12438223 | 22 | C | PROBENECID/COLCHICINE | 2 | Unknown | 0 | TABLET | |||||||||||
| 124382232 | 12438223 | 23 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Unknown | 0 | UNSPECIFIED | ||||||||||
| 124382232 | 12438223 | 24 | C | ALBUTEROL. | ALBUTEROL | 1 | Unknown | 0 | UNSPECIFIED | ||||||||||
| 124382232 | 12438223 | 25 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Unknown | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124382232 | 12438223 | 1 | Psoriatic arthropathy |
| 124382232 | 12438223 | 2 | Psoriatic arthropathy |
| 124382232 | 12438223 | 4 | Asthma |
| 124382232 | 12438223 | 5 | Inflammatory pain |
| 124382232 | 12438223 | 6 | Pain |
| 124382232 | 12438223 | 7 | Peripheral swelling |
| 124382232 | 12438223 | 8 | Mineral supplementation |
| 124382232 | 12438223 | 9 | Inflammation |
| 124382232 | 12438223 | 11 | Hypertension |
| 124382232 | 12438223 | 14 | Psoriatic arthropathy |
| 124382232 | 12438223 | 15 | Hypersensitivity |
| 124382232 | 12438223 | 16 | Hypersensitivity |
| 124382232 | 12438223 | 17 | Asthma |
| 124382232 | 12438223 | 18 | Sleep disorder |
| 124382232 | 12438223 | 19 | Weight decreased |
| 124382232 | 12438223 | 20 | Restless legs syndrome |
| 124382232 | 12438223 | 21 | Dry mouth |
| 124382232 | 12438223 | 22 | Gout |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124382232 | 12438223 | OT |
| 124382232 | 12438223 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124382232 | 12438223 | Asthma | |
| 124382232 | 12438223 | Diabetes mellitus | |
| 124382232 | 12438223 | Headache | |
| 124382232 | 12438223 | Malaise | |
| 124382232 | 12438223 | Uterine disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124382232 | 12438223 | 1 | 201505 | 0 | ||
| 124382232 | 12438223 | 2 | 2014 | 2015 | 0 | |
| 124382232 | 12438223 | 4 | 201605 | 0 | ||
| 124382232 | 12438223 | 14 | 2009 | 0 | ||
| 124382232 | 12438223 | 17 | 2005 | 0 | ||
| 124382232 | 12438223 | 18 | 2013 | 0 | ||
| 124382232 | 12438223 | 19 | 2015 | 0 |